Increase confidence through expert-backed antibody testing

Autoimmune demyelinating neuropathies include several progressive conditions — among them chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome (GBS), chronic immune sensory polyradiculopathy (CISP), and distal acquired demyelinating sensory (DADS) neuropathy — that share overlapping motor and/or sensory features with other peripheral neuropathies. Many of these presentations are associated with autoantibody biomarkers, which can not only help with diagnosis, but in some cases aid in selecting optimal treatment.

Mayo Clinic Laboratories’ approach to testing for immune-mediated demyelinating neuropathies involves utilizing highly accurate assays to identify the specific biomarkers associated with the harmful immune response. Our assays were developed by autoimmune neurology experts and utilize pioneering methods, such as live-cell flow cytometry, that enable increased specificity to detect for antibody presence and provide diagnostic certainty when there is doubt.